Comparing Cisplatin and Carboplatin Treatments for Lung Cancer
Author Information
Author(s): Sculier J-P, Lafitte J-J, Paesmans M, Thiriaux J, Alexopoulos C G, Baumöhl J, Schmerber J, Koumakis G, Florin M C, Zacharias C, Berghmans T, Mommen P, Ninane V, Klastersky J
Primary Institution: Institut Jules Bordet
Hypothesis
Does the combination of moderate-dose cisplatin and carboplatin improve survival in patients with stage IV non-small-cell lung cancer compared to cisplatin alone?
Conclusion
The study found no significant improvement in response or survival when using the combination of cisplatin and carboplatin compared to cisplatin alone.
Supporting Evidence
- There was a 27% objective response rate to MIP and a 33% response rate to CarboMIP.
- Median survival times were 28 weeks for MIP and 32 weeks for CarboMIP.
- 1-year survival rates were 24% for MIP and 23% for CarboMIP.
Takeaway
Doctors wanted to see if mixing two cancer drugs would help patients live longer, but it didn't make a difference compared to just using one of the drugs.
Methodology
A phase III randomized trial was conducted with patients receiving either the MIP regimen or the CarboMIP regimen.
Limitations
The study did not include patients with prior chemotherapy and had a limited follow-up period.
Participant Demographics
Patients with stage IV non-small-cell lung cancer, with no prior chemotherapy.
Statistical Information
P-Value
0.34
Confidence Interval
95% CI, 19–34 for MIP and 95% CI, 24–41 for CarboMIP
Statistical Significance
p=0.34
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website